FAFabiana Alves

Fabiana Alves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabiana Alves has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

    by Sauman Singh-Phulgenda, Prabin Dahal, Brittany J. Maguire, Jorge Alvar, Fabiana Alves, Mitali Chatterjee, Carlos Costa, Simon L. Croft, Philippe J. Guerin, Dinesh Mondal, et al.

    Background: Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently in the elimination phase in the Indian subcontinent (ISC) and being targeted for elimination by 2030 in East Africa (EA). Maintaining the necessary financial and political commitments to achieve and sustain the current elimination efforts remains challenging. As with other NTDs, VL research is constrained by limited funding, and drug development has relied largely on partnerships between not-for-profit organisations and the pharmaceutical industry. Conducting robust clinical studies remains difficult, and therapeutic innovations have been limited. However, re-use of existing data offers an untapped opportunity to generate new evidence. Methods: We describe the process of developing a global VL research agenda and the establishment of an individual participant data (IPD) platform at the Infectious Diseases Data Observatory (IDDO). Key steps included a systematic scoping review of VL clinical trials, consultations with the Scientific Advisory Committee, expert and public reviews, and implementation of an equitable governance framework to harmonise and share IPD. Results: The VL research agenda, finalised in 2019, identified priority methodological and clinical questions suited to IPD analyses. The IDDO VL platform currently hosts harmonised data from nearly 15,000 patients across more than 50 studies (VL and post-kala-azar dermal leishmaniasis, PKDL). The platform is an inclusive resource guided by an equitable governance framework and provides a critical asset to support new evidence generation and can serve as a historical data to support accelerated drug development. Conclusions: The development of a global VL research agenda has provided an inventory of priority research questions of public health importance. A shared IPD platform aligned with this agenda was developed to complement ongoing global efforts. In addition, such a platform can accelerate secondary evidence generation, support methodological innovation and inform future trial designs and policy. Sustained collaboration and investment are needed to maximise the scientific and public health value of data re-use in VL and PKDL.


  • Open Access

    Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

    by Wan‐Yu Chu, Om Prakash Singh, Shyam Sundar, Dinesh Mondal, Krishna Pandey, Pradeep Das, Ignace C. Roseboom, Sheeraz Raja, Ana Torres, Eugenia Carrillo, et al.

    Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasites reside. Liposomal amphotericin B (LAmB) plays a key role in the treatment of PKDL. The mononuclear phagocyte system (MPS) is crucial in the distribution of liposomal drugs as well as the leishmaniasis pathophysiology. This study focused on characterizing the interaction between LAmB pharmacokinetics, the MPS, and parasite dynamics for optimal dosing of LAmB in PKDL. Clinical trial data from the Indian subcontinent, involving short‐course LAmB administered alone or with miltefosine, were analyzed using nonlinear mixed‐effects modeling. The pharmacokinetics of LAmB were best described by a two‐compartment model with a saturable LAmB uptake by the MPS. The maximum MPS uptake capacity was modeled with a baseline component and an additional disease‐related component relative to the parasite burden. As treatment progressed, MPS capacity decreased with declining parasite load, resulting in a median 54% increase in the systemic LAmB exposure (AUC 0‐24h ) by the end of treatment. Simulations suggested that a similar parasite clearance could be achieved with a 50% lower total LAmB dose, supporting the potential efficacy of reduced dosing regimens. Combining LAmB and miltefosine further accelerated parasite clearance compared to LAmB alone. This study highlights the importance of understanding the bidirectional interactions between LAmB pharmacokinetics and parasite infection for interpreting systemic exposure and optimizing treatment approaches. If confirmed in clinical trials, reduced LAmB dosing strategies could enable more rational and cost‐effective management of PKDL and other dermal leishmaniases.


  • Open Access

    Design, Conduct, Analysis, and Reporting of Therapeutic Efficacy Studies in Visceral Leishmaniasis: A Systematic Review of Published Reports, 2000–2021

    by Prabin Dahal, Sauman Singh-Phulgenda, Caitlin Naylor, Matthew Brack, Mitali Chatterjee, Fabiana Alves, Philippe J. Guerin, Kasia Stepniewska

    : A systematic review (SR) of published efficacy studies in visceral leishmaniasis (VL) was undertaken to describe methodological aspects of design, conduct, analysis, and reporting. Studies published during 2000–2021 and indexed in the Infectious Diseases Data Observatory VL library of clinical studies were eligible for inclusion (N = 89 studies). Of the 89 studies, 40 (44.9%) were randomized, 33 (37.1%) were single-armed, 14 (15.7%) were nonrandomized multiarmed studies, and randomization status was unclear in two (2.2%). After initial screening, disease confirmation was done by microscopy in 26 (29.2%) and by a combination of serology and microscopy in 63 (70.8%). Post-treatment follow-up duration was 6 months in 11 (12.4%) studies. Confirmation of relapse was solely based on clinical suspicion in four (4.5%) studies, parasitological demonstration in 64 (71.9%), using molecular/serological/parasitological method in 6 (6.7%), and there was no information in 15 (16.9%). Of the 40 randomized studies, sample size calculation was reported in only 22 (55.0%) studies. This review highlights substantial variations in definitions adopted for disease diagnosis and therapeutic outcomes suggesting a need for a harmonized trials protocol.


  • Open Access

    A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

    by Shyam Sundar, Krishna Pandey, Dinesh Mondal, Major Madhukar, Roshan Kamal Topno, Ashish Kumar, Vinod Kumar, Deepak Kumar Verma, Jaya Chakravarty, Rahul Chaubey, et al.

    In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefosine (MF), is low and ocular toxicity has been observed with this exposure period. We assessed the safety and efficacy of two shorter-course treatments: liposomal amphotericin B (LAmB) alone and combined with MF. An open-label, phase II, randomized, parallel-arm, non-comparative trial was conducted in patients with parasitologically confirmed PKDL, 6 to ≤60 years. Patients were assigned to 20 mg/kg LAmB (total dose, in five injections over 15 days) alone or combined with allometric MF (3 weeks). The primary endpoint was definitive cure at 12 months, defined as complete resolution of papular and nodular lesions and >80% re-pigmentation of macular lesions. Definitive cure at 24 months was a secondary efficacy endpoint. 118/126 patients completed the trial. Definitive cure at 12 months was observed in 29% (18/63) patients receiving LAmB and 30% (19/63) receiving LAmB/MF (mITT), increasing to 58% and 66%, respectively, at 24 months. Most lesions had resolved/improved at 12 and 24 months for patients receiving LAmB (90%, 83%) and LAmB/MF (85%, 88%) by qualitative assessment. One death, unrelated to study drugs, was reported; no study drug-related serious adverse events were observed. The most frequent adverse drug reactions were MF-related vomiting and nausea, and LAmB-related hypokalaemia and infusion reactions. Most adverse events were mild; no ocular adverse events occurred. Both regimens are suitably safe and efficacious alternatives to long-course MF for PKDL in South Asia. CTRI/2017/04/008421. Post-kala-azar dermal leishmaniasis (PKDL) is a skin rash which can appear after successful treatment of visceral leishmaniasis caused by the parasite Leishmania donovani. Although not life-threatening for the patient, this condition can be associated with social stigma, and the sandfly that transmits the disease can become infected after feeding on patients with PKDL lesions. Therefore, all patients are treated to control visceral leishmaniasis within the Southeast Asia kala-azar elimination initiative. It is difficult to justify the use of existing treatments in patients who are otherwise generally well, since they are prolonged, potentially toxic, and expensive. We designed a trial at two sites in India and one in Bangladesh to assess the efficacy and safety of two treatment options for patients with PKDL: 20 mg/kg liposomal amphotericin B in monotherapy and 20 mg/kg liposomal amphotericin B in combination with three weeks of miltefosine. These two regimens were found to have a similar efficacy to the current first line treatment, but with a much shorter treatment duration, which also reduces the risk of side-effects and makes them particularly useful in the current context of elimination in the region.


  • Open Access

    Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies

    by Prabin Dahal, Sauman Singh-Phulgenda, James Wilson, Glaucia Cota, Koert Ritmeijer, Ahmed Musa, Fabiana Alves, Kasia Stepniewska, Philippe J Guerin

    Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises the transfusion practices adopted in VL efficacy studies using the Infectious Diseases Data Observatory VL clinical trials library. Of the 160 studies (1980–2021) indexed in the IDDO VL library, description of blood transfusion was presented in 16 (10.0%) (n=3459 patients) studies. Transfusion was initiated solely based on haemoglobin (Hb) measurement in nine studies, combining Hb measurement with an additional condition (epistaxis/poor health/clinical instability) in three studies and the criteria was not mentioned in four studies. The Hb threshold range for triggering transfusion was 3–8 g/dL. The number of patients receiving transfusion was explicitly reported in 10 studies (2421 patients enrolled, 217 underwent transfusion). The median proportion of patients who received transfusion in a study was 8.0% (Interquartile range: 4.7% to 47.2%; range: 0–100%; n=10 studies). Of the 217 patients requiring transfusion, 58 occurred before VL treatment initiation, 46 during the treatment/follow-up phase and the time was not mentioned in 113. This review describes the variation in clinical practice and is an important initial step in policy/guideline development, where both the patient's Hb concentration and clinical status must be considered.


  • Open Access

    Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study

    by Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, et al.

    Treatment for post-kala-azar dermal leishmaniasis (PKDL) in Sudan is currently recommended only for patients with persistent or severe disease, mainly because of the limitations of current therapies, namely toxicity and long hospitalization. We assessed the safety and efficacy of miltefosine combined with paromomycin and liposomal amphotericin B (LAmB) for the treatment of PKDL in Sudan. An open-label, phase II, randomized, parallel-arm, non-comparative trial was conducted in patients with persistent (stable or progressive disease for ≥ 6 months) or grade 3 PKDL, aged 6 to ≤ 60 years in Sudan. The median age was 9.0 years (IQR 7.0–10.0y) and 64% of patients were ≤12 years old. Patients were randomly assigned to either daily intra-muscular paromomycin (20mg/kg, 14 days) plus oral miltefosine (allometric dose, 42 days)–PM/MF–or LAmB (total dose of 20mg/kg, administered in four injections in week one) and oral miltefosine (allometric dose, 28 days)–AmB/MF. The primary endpoint was a definitive cure at 12 months after treatment onset, defined as clinical cure (100% lesion resolution) and no additional PKDL treatment between end of therapy and 12-month follow-up assessment. 104/110 patients completed the trial. Definitive cure at 12 months was achieved in 54/55 (98.2%, 95% CI 90.3–100) and 44/55 (80.0%, 95% CI 70.2–91.9) of patients in the PM/MF and AmB/MF arms, respectively, in the mITT set (all randomized patients receiving at least one dose of treatment; in case of error of treatment allocation, the actual treatment received was used in the analysis). No SAEs or deaths were reported, and most AEs were mild or moderate. At least one adverse drug reaction (ADR) was reported in 13/55 (23.6%) patients in arm 1 and 28/55 (50.9%) in arm 2, the most frequent being miltefosine-related vomiting and nausea, and LAmB-related hypokalaemia; no ocular or auditory ADRs were reported. The PM/MF regimen requires shorter hospitalization than the currently recommended 60-90-day treatment, and is safe and highly efficacious, even for patients with moderate and severe PKDL. It can be administered at primary health care facilities, with LAmB/MF as a good alternative. For future VL elimination, we need new, safe oral therapies for all patients with PKDL. ClinicalTrials.gov NCT03399955, https://clinicaltrials.gov/study/NCT03399955 ClinicalTrials.gov ClinicalTrials.gov Post-kala-azar dermal leishmaniasis (PKDL) is a skin rash which appears months or years after successful treatment of visceral leishmaniasis (VL) caused by Leishmania donovani. It is not life-threatening, and since patients with PKDL are otherwise well and may self-heal, they rarely seek treatment. Sandflies (the parasite vector) become infected with L. donovani after feeding on patients with PKDL, and so, from a public health perspective, ideally all patients, regardless of severity, would be treated to control VL, even those with mild disease. However, current therapies are toxic and/or require long hospitalization. Therefore, treatment is recommended only for patients with persistent disease or severe PKDL. We conducted a phase II trial in 110 patients with PKDL to assess two antimony-free combination therapies and demonstrated that a paromomycin/miltefosine regimen was suitably safe and highly efficacious even for moderate and severe PKDL, and could be administered at primary health centres. This makes it more patient-friendly, which is important since most people with PKDL are children. A liposomal amphotericin B/miltefosine regimen is a good alternative for implementation in hospitals for a shorter period. To support VL elimination in East Africa, new, safe, oral therapies for all patients with PKDL are still needed, including mild cases and women of reproductive potential unwilling or unable to use contraception.


  • Open Access

    Design, conduct, analysis, and reporting of therapeutic efficacy studies in Visceral Leishmaniasis: A systematic review of published reports, 2000-2021

    by Prabin Dahal, Sauman Singh-Phulgenda, Caitlin Naylor, Matthew Brack, Mitali Chatterjee, Fabiana Alves, Philippe J Guerin, Kasia Stepniewska

    A systematic review (SR) of published efficacy studies in visceral leishmaniasis (VL) was carried out to describe methodological aspect of design, analysis, conduct and reporting. Studies published during 2000-2021 and indexed in the Infectious Diseases Data Observatory (IDDO) VL library of clinical studies were eligible for inclusion (n=89 studies). The IDDO VL library is a living SR of prospective therapeutic studies (PROSPERO: CRD42021284622) and is updated bi-annually. A total of 40 (44.9%) studies were randomised, 33 (37.1%) were single-armed, 14 (15.7%) were non-randomised multi-armed studies, and randomisation was unclear in 2 (2.2%). After initial screening, patients were enrolled into the study upon confirmation of VL using parasitological method in 26 (29.2%), and serological and parasitological method in 63 (70.8%). Post-treatment follow-up duration was 6months in 11 (12.4%) studies. Relapse was defined solely based on clinical suspicion in 4 (4.5%) studies, parasitological demonstration in 64 (71.9%), using molecular/serological/parasitological in 6 (6.7%), and was unclear in 15 (16.9%). Quality control of laboratory measures adopted was unclear in 66 (74.2%) studies, sample size calculation was reported in only 34 (38.2%) studies, and cured proportion was presented only as a point estimate in 39 (43.8%) studies. This review highlights substantial variations in definitions adopted for patient screening, disease diagnosis and therapeutic outcomes suggesting an urgent need for harmonisation of VL clinical trials protocol.


  • Open Access

    Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: a systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform

    by Sauman Singh-Phulgenda, Rishikesh Kumar, Prabin Dahal, Abdalla Munir, Sumayyah Rashan, Rutuja Chhajed, Caitlin Naylor, Brittany J. Maguire, Niyamat Ali Siddiqui, Eli Harriss, et al.

    Background: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL endemic areas. We conducted a systematic scoping review to assess the characteristics of published PKDL clinical studies, understand the scope of research and explore the feasibility and value of developing a PKDL individual patient data (IPD) platform. Methods: A systematic review of published literature was conducted to identify PKDL clinical studies by searching the following databases: PubMed, Scopus, Ovid Embase, Web of Science Core Collection, WHO Global Index Medicus, PASCAL, Clinicaltrials.gov, Ovid Global Health, Cochrane Database and CENTRAL, and the WHO International Clinical Trials Registry Platform. Only prospective studies in humans with PKDL diagnosis, treatment, and follow-up measurements between January 1973 and March 2023 were included. Extracted data includes variables on patient characteristics, treatment regimens, diagnostic methods, geographical locations, efficacy endpoints, adverse events and statistical methodology. Results: A total of 3,418 records were screened, of which 56 unique studies (n=2,486 patients) were included in this review. Out of the 56 studies, 36 (64.3%) were from India (1983-2022), 12 (21.4%) from Sudan (1992-2021), 6 (10.7%) were from Bangladesh (1991-2019), and 2 (3.6%) from Nepal (2001-2007). Five (8.9%) studies were published between 1981-1990 (n=193 patients), 10 (17.9%) between 1991-2000 (n=230 patients), 10 (17.9%) between 2001-2010 (n=198 patients), and 31 (55.4%) from 2011 onwards (n=1,865 patients). Eight (14.3%) were randomised clinical trials, and 48 (85.7%) were non-randomised studies. The median post-treatment follow-up duration was 365 days (range: 90-540 days) in 8 RCTs and 360 days (range: 28-2,373 days) in 48 non-randomised studies. Disease diagnosis was based on clinical criterion in 3 (5.4%) studies, a mixture of clinical and parasitological methods in 47 (83.9%) and was unclear in 6 (10.7%) studies. Major drugs used for treatment were miltefosine (n=636 patients), liposomal amphotericin B (L-AmB) (n=508 patients), and antinomy regimens (n=454 patients). Ten other drug regimens were tested in 270 patients with less than 60 patients per regimen. Conclusions: Our review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices. PROSPERO: CRD42021295848 Author summary: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which mostly manifests after successful treatment of visceral leishmaniasis (VL) and is characterised by macular, papular, nodular, erythematous, or polymorphic rashes. PKDL is a public health problem in VL endemic areas, as recent infectivity studies show that L. donovani parasites can be found in PKDL lesions and remain infectious to sandfly vectors. There are numerous gaps in our existing knowledge of PKDL, including its pathology, immunology, and risk factors associated with therapeutic outcomes. Currently recommended treatments are either expensive (liposomal amphotericin-B), have raised safety concerns (especially for antimony regimens), or require long treatment duration (e.g. miltefosine). In order to scope the measure of evidence supporting therapeutic efficacy recommendations for PKDL patients, we conducted a systematic literature review. Our systematic review identified 56 PKDL studies describing 2,486 patients, with a majority of the studies (31 studies and 1,865 patients) published from 2010 onwards. The Infectious Diseases Data Observatory (IDDO) already have an established data platform for VL, and the IDDO VL data platform currently hosts a critical mass of data from efficacy trials in VL conducted over the past 20 years. Based on the identified volume of data, with a substantial number of studies being relatively recent, we believe that the establishment of a PKDL data platform is feasible. Creating a platform to facilitate the sharing of the datasets would enable in-depth IPD meta-analyses with existing data to address several knowledge gaps of PKDL and guide future research priorities. With the help of relevant stakeholders, the global PKDL community and sufficient resources, a PKDL data platform can be realised and help address key research gaps.

  • Top Cited Papers
    Open Access

    Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

    by Ahmed M Musa, Jane Mbui, Rezika Mohammed, Joseph Olobo, Koert Ritmeijer, Gabriel Alcoba, Gina Muthoni Ouattara, Thaddaeus Egondi, Prossy Nakanwagi, Truphosa Omollo, et al.

    Background: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. Methods: An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days). The primary endpoint was definitive cure after 6 months. Results: Of 439 randomized patients, 424 completed the trial. Definitive cure at 6 months was 91.2% (155 of 170) and 91.8% (156 of 170) in the PM/MF and SSG/PM arms in primary efficacy modified intention-to-treat analysis (difference, 0.6%; 97.5% confidence interval [CI], −6.2 to 7.4), narrowly missing the noninferiority margin of 7%. In the per-protocol analysis, efficacy was 92% (149 of 162) and 91.7% (155 of 169) in the PM/MF and SSG/PM arms (difference, −0.3%; 97.5% CI, –7.0 to 6.5), demonstrating noninferiority. Treatments were well tolerated. Four of 18 serious adverse events were study drug–related, and 1 death was SSG-related. Allometric dosing ensured similar MF exposure in children (<12 years) and adults. Conclusions: PM/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs safety profiles. With 1 less injection each day, reduced treatment duration, and no risk of SSG-associated life-threatening cardiotoxicity, PM/MF is a more patient-friendly alternative for children and adults with primary visceral leishmaniasis in eastern Africa. Clinical Trials Registration: NCT03129646.


  • Open Access

    Control of visceral leishmaniasis in East Africa: fragile progress, new threats

    by Elin Hoffmann Dahl, Hamdan Mustafa Hamdan, Lexson Mabrouk, Sultani Hadley Matendechero, Tesfahun Bishaw Mengistie, Mousab Siddig Elhag, Mounir Lado, Cherinet Adera, Atia Abdalla Atia, Julien Potet, et al.